Saint Ismier, France | June 2019
Auditory Steady-State Response (ASSR) is a translational EEG biomarker of the brain’s ability to process sensory information. 40Hz ASSR responses are specifically lowered in patients and rodent models of schizophrenia, making it relevant to evaluate antipsychotic drugs
Saint Ismier, France | MAY 5 2019
What are HPD? Mesio-temporal lobe epilepsy (MTLE) represents one of the most common forms of focal epilepsies. Generally resistant to most pharmacological treatments, this type of epilepsy affects about 10% of the total epileptic population. SynapCell has an extensive expertise modeling the
Saint Ismier, France | April 2019
What are SWD? Patients with Absence Epilepsy show generalized, non-convulsive seizures & typical Spike-and-Wave Discharges. The GAERS model displays spontaneous SWD and recapitulates most human disease features, making it clinically-relevant to evaluate new drugs for Absence #Epilepsy.
Basel, Switzerland | MAY 7 2019
Did you know that Electro-Encephalography (EEG, EPhys) has the power to secure your Ph2 Efficacy phase as soon as at the preclinical step? This is all about predictive, objective and clinically-relevant biomarkers for Epilepsy, Parkinson's Disease and disorders involving the brain information
Miami, USA | MAY 22-25 2019
As a key player in Epilepsy, SynapCell will participate to the Anti-Epileptic Drugs and Device Trials XI, taking place in Miami, Florida. Take a moment to have a one-to-one discussion with Corinne Roucard, founder and CEO of SynapCell and learn more on our capabilitries to secure your epilepsy
Lisbon | March 26-31 2019
Phase-amplitude coupling as a new biomarker of PD Discover the science behind at the #ADPD meeting in Lisbon this month TRANSLATIONAL NEUROSCIENCE Friday March 29 662: IDENTIFICATION OF A SPECIFIC PHASE-AMPLITUDE COUPLING IN A RAT MODEL OF PARKINSON'S DISEASE 686: IMPROVING DRUG DISCOVERY IN
Rockville, MD | March 25-28 2019
From EEG signatures to predictive biomarkers. Learn how to accelerate lead selection with objective, measurable and reproducible readouts on preclinical efficacy programs. Don’t miss our Poster communication entitled EEG biomarkers to improve the discovery of new neurotherapeutics. Save the
Term of the month | SynapCell
Phase-amplitude coupling can help study the interactions between neuronal oscillations. It describes a phenomenon whereby the amplitude of higher frequency activity is modulated by the phase of lower frequency activity, providing relevant information on #Brain connectivity. #EEG Phase-amplitude
Term of the month | SAINT ISMIER, FRANCE
Word of the month : ERPs Event-related potentials are defined as the modification of the electrical activity of the nervous system in response to an external stimulation. ERPs are useful to monitor how the brain processes new sensory information. Defects in information processing like in
Saint Ismier, France | New Year's Day 2019
We hope you had a great year! 2018 has kept us busy taking care of various exciting research projects while exploring new opportunities to expand our offering with more translational and predictive biomarkers in the field of neurodegenerative disorders, Parkinson's and much more. We also
San Diego, CA | Nov 5 2018
Cavion’s T-Type Calcium Channel Modulator CX-8998 is Superior to Current Standard of Care in Suppressing Absence Seizures in SynapCell's Genetic Absence Epilepsy Model (GAERS) Cavion, Inc., a clinical stage biotechnology company developing novel therapeutics for neurological diseases,
San Diego, CA | Oct 29 2018
Absence epilepsy is a form of epileptic syndrome where patients show generalized non-convulsive seizures characterized by a brief unresponsiveness to environmental stimuli and cessation of activity. In human, typical absence seizures are associated with bilateral, synchronous and regular
New York City, USA | Oct 25, 2018
Meet Corinne Roucard Oct 25 at The Michael J. Fox Foundation for Parkinson's Research conference in NYC and learn more on the use of predictive EEG Biomarkers for in vivo efficacy testing of new drugs for Parkinson's disease. #eeg #biomarkers #invivo
Yokohama, Japan | OCT 10-12, 2018
BioJapan is approaching! Our team is heading to Osaka on October 9 for the B2Match partnering event and to Yokohama October 10-12 for BioJapan2018. A unique occasion to meet with leading researchers from Japan and share insights on the benefits of Pharmaco-EEG in preclinical drug discovery! We
San Diego, CA | Nov 4-7 2018
We'll exhibit at SfN 2018 in San Diego! 2018 has been rich in innovations thanks to unprecedented R&D efforts in the lab. The team will present 3 posters that describe how EEG and Pharmaco-EEG testing allow for acurate monitoring of a compound effect on the brain in translational models of CNS
Brain-focused CRO, we support your Drug Discovery programs in Epilepsy, Parkinson, Alzheimer, Schizophrenia and Essential Tremor with predictive and translational Pharmacodynamic assays in vivo at the Preclinical stage.
BOSTON, MA | June 4-7 2018
Meet the team and discover how we help solve uncertainty with our translational PharmacoEEG programs and predictive biomarkers for CNS Drug Discovery.
Madrid, Spain | MAY 13-16 2018
SynapCell will participate to the 14th EILAT Conference on New Antiepileptic Drugs and Devices in Madrid May 13-16. This will be the occasion for us to announce the renewal of SynapCell woldwide-exclusive licence on the GAERS rat model, which confirms our strong will to continue supporting your
Saint Ismier, France | MARCH 21 2018
Baptisée NeurOsyn-alliance, cette solution unique et innovante, fruit d’une étroite collaboration entre les deux sociétés françaises, permet de simplifier le parcours de sélection de candidats médicaments pour les industriels. Il s’agit d’une approche combinée 2D 3D basée sur
Saint Ismier, France | MARCH 19 2018
Installée dans de nouveaux locaux où sont réunies toutes ses activités, la société SynapCell, spécialisée dans l’expertise préclinique de médicaments pour les pathologies du cerveau, accélère sa croissance. “Notre pari il y a trois ans de cibler d’autres pathologies que
Grenoble, France | FEB 12 2018
Today is the International Epilepsy Day. #EPILEPSYDAY An epileptic disorder is a chronic neurological condition characterized by recurrent epileptic seizures. Epileptic seizures are characterized by a hypersynchrony and hyperexcitability of one, or several, neural networks, leading to the
Washington, D.C | Nov 15 2017
Neuroservice and SynapCell are very pleased to announce the launch of a joint product, neurOsyn. This new offer combines a unique in vitro and in vivo approach to document your compound’s effects on brain oscillations. Neuroservice has developed over the last 3 years in vitro Multi-Electrode
Washington, DC | Nov 11-15 2017
Plan to attend Neuroscience 2017 in DC this year? SynapCell will be there along with stunning outcomes. BOOTH#2126 *Effect of amantadine on L-DOPA-induced cortical oscillations in the 6-OHDA rat Session Type: Poster Session Number: 210 Session Title: Parkinson's Disease: Preclinical
Paris, France | Sep 2-5 2017
Meet our team at the 30th ECNP Congress of Applied and Translational Neuroscience Learn more on our Predictive Decision-making solutions for CNS Drug Discovery. *Auditory steady state responses in rodents, a new tool for drug discovery in schizophrenia? Poster details: Abstract
Miami, USA | June 2017
Just back from Miami, USA where I had the chance to attend The Anti Epileptic Drug and Devices Trials Conference two weeks ago. We have been very proud to see that SynapCell now belongs to the restricted veteran club of this meeting, as it’s indeed been already 8 years since we’ve started
Miami, USA | May 17-19 2017
SynapCell to unveil unprecedented advances in Epilepsy at the Antiepileptic Drug Trials Conference. Contact us to select a convenient time for you to meet Corinne, CEO and founder of SynapCell. Conference Purpose The conference focuses on issues surrounding AEDD development, ranging from
Vienna, Austria | March 29 - April 2, 2017
Dear all, We are pleased to announce that we will present our latest advances in Parkinson's Disease and Dyskenesia during the AD/PD 2017 Conference. We look forward to meeting with you there! POSTER #320 Amantadine decreases L-DOPA induced cortical gamma oscillations in the 6-OHDA rat All
Grenoble and Salt Lake City | 03/11/2016
SYNAPCELL RE-ESTABLISHES PARTNERSHIP WITH THE UNIVERSITY OF UTAH TO SCREEN NOVEL ANTI-EPILEPTIC MEDICATIONS The University of Utah has awarded a subcontract to SynapCell as part of the NIH/NINDS Epilepsy Therapy Screening Program (ETSP). The partnership between SynapCell and the University of
San Diego, USA | 12 - 16 NOV 2016
Save the Date! SynapCell will attend the Neuroscience 2016 Meeting. We look forward to unveiling to you our latest advances in Translational CNS Drug Discovery Services. Make the Right Decision. Stop Guessing. Meet us in San Diego!
Madrid, Spain | 26 - 29 June 2016
SynapCell will attend the 13th EILAT Conference on New Antiepileptic Drugs and Devices! Corinne ROUCARD, CEO and co-Founder will present you how the MTLE model provides an efficient way to identify new treatment for drug-resistant forms of focal epilepsies. Make the Right Decision. Stop
Berlin, Germany | 19 - 23 June 2016
Our experts will present 2 Posters on the use of EEG Biomarkers, that are both Predictive and Translational for your Parkinson's and Essential Tremor's Drug Discovery program. We're looking forward to meeting you there! Make the Right Decision. Stop Guessing.
Grenoble | February 26 2016
We are delighted to share with you the publication of our article about the MTLE mouse: a model of focal epilepsy in CNS Neuroscience and Therapeutics. Our work is entitled "Differential effects of antiepileptic drugs on focal seizures in the intrahippocampal kainate mouse model of Mesial Temporal
Chicago | 17 - 21 October 2015
A week is already gone since I got back from the amazing adventure that Neuroscience 2015 was, with 29,033 attendees. What a pleasure to meet so many people with whom I have been in contact from afar, bringing together a face to a name! Our booth was such a great opportunity to take time to talk
Chicago | 17 - 21 October 2015
Stop guessing; think outside the box with EEG! We can help you select the most effective lead right from the earliest phase, avoiding time-consuming and costly trials. Strong of our 10 years experience of EEG in rodent models, let us show you how easy we can make it for you! We open a wide
Chicago | 17 - 21 October 2015
Coming up in a month in Chicago, Neuroscience 2015 is the world's largest source of emerging news on brain science and health, with more than 30,000 attendees! Lectures, symposia, and thousands of posters provide new understanding of how the brain works. Leading researchers explore brain
Turin | 23 - 24 September 2015
SynapCell is involved in the funded EU Project NEURINOX. Together with the project consortium, we will be hosting a symposium on Innovative Concepts for Treating Neurodegenerative Diseases. This will be held over the 23rd and 24th September at the Molecular Biotechnology Centre in Torino (Italy),
Amsterdam | August 29 - September 1st 2015
At the end of the summer, SynapCell is going to take part of the major event in neuropsychopharmacology: the annual ECNP congress, held this year in Amsterdam. Established in 1987 at the instigation of European scientists, ECNP is committed to ensuring that advances in the understanding of brain
Park city, Utah | 17 - 20 May 2015
Two majors congresses for epilepsy drug discovery are taking place this May in the USA, and of course we will be there! First will be held the Antiepileptic Drug and Device (AED) Trials XIII Conference in Miami on May 13 to 15, followed from May 17 to 20 by the ADD symposium in Park city,
Miami | 13-15 May 2015
Two majors congresses for epilepsy drug discovery are taking place this May in the USA, and of course we will be there! First will be held the Antiepileptic Drug and Device (AED) Trials XIII Conference in Miami on May 13 to 15, followed from May 17 to 20 by the ADD symposium in Park city, Utah #
France | 2nd December 2014
Synapcell to assess the potential of UCB's candidate molecules in the field of epilepsy. The two-year agreement will take advantage of SynapCell’s MTLE (mesial temporal lobe epilepsy) mouse solutions. More than 65 million people world-wide are affected by epilepsy (WHO). Full drug development
Madrid | August 31 - September 3 2014
I am just back from Madrid (Spain) where I attended Eilat XII, the conference on anti-epileptic drugs (AEDs). I believe the conference was a success, it brought together people from biotech and pharma industries, clinicians and academics to discuss epilepsy and AEDs, whether already on the
Madrid | August 31 – September 3 2014
Relocated in Madrid, Spain, August 31 - September 3 for this forthcoming edition, the twelfth Eilat Conference on new antiepileptic drug (AEDs) will be introducing debates as a new feature. These debates are added to the previous format of in-depth progress report on new antiepileptic drugs in
Grenoble | APRIL 24TH, 2014
The recent clinical data obtained with a new antiepileptic drug (AED) candidate called pitolisant, developed by Bioprojet, in an early Phase II study confirms the interest in SynapCell's strategic approach, associating animal models and EEG, as a translational marker of brain's function. Moreover,
Salt Lake City | January 29th, 2014
The University of Utah awards a subcontract to SynapCell to expand anti-seizure drug screening and testing capabilities in animal models of therapy-resistant epilepsy. The University of Utah has awarded a one-year subcontract to SynapCell under the Anticonvulsant Screening Program (ASP)